Santen stock gets a new eye care link after AVS sale

Published on 10/07/2026 at 00:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Santen stock was last at JPY 1,683.50 on October 6, 2026, up 1.42 percent as the eye-care group reshapes its device portfolio. Nine analysts set a Buy consensus with a JPY 2,358.90 target.

Santen, JP3336000009, Illustration mit AI erstellt.

Santen Pharmaceutical Co., Ltd. (ISIN JP3336000009) was last at JPY 1,683.50 on the Tokyo Stock Exchange on October 6, 2026, up 1.42 percent from the previous close. The company has also put a major ophthalmic device asset into new ownership, creating a clearer manufacturing link between Santen and SpyGlass Pharma.

AVS sale reshapes device exposure

On October 1, 2026, SpyGlass Pharma acquired 100 percent of Advanced Vision Science, a wholly owned Santen subsidiary, according to StockTitan. The transaction gives SpyGlass control of intraocular lens manufacturing capacity while AVS remains the exclusive supplier of several lens types to Santen for commercialization in Japan.

The arrangement matters because AVS supplied lenses for SpyGlass Pharma's two Phase 3 trials of its BIM-IOL System. Santen therefore retains a commercial supply relationship after the ownership change, while the sale transfers manufacturing assets and execution responsibility to a specialized eye-care company.

Quarterly figures set the baseline

Santen's quarter ended June 30, 2026, produced revenue of JPY 68.96 billion and net income of JPY 7.19 billion, figures reported in the latest financial context from JPX Market Explorer. The company had also set fiscal 2027 guidance for revenue of JPY 311.0 billion, operating profit of JPY 49.5 billion, net income of JPY 39.5 billion and basic earnings per share of JPY 124.42.

That guidance gives investors a concrete yardstick for the next report: quarterly revenue of JPY 68.96 billion represents 22.2 percent of the full-year revenue target, while quarterly net income of JPY 7.19 billion represents 18.2 percent of the annual target. The comparison is directional because the quarter is only one reporting period, but it shows the scale of the remaining execution task.

Consensus target stays above price

Investing.com listed a Buy consensus from 9 analysts on September 8, 2026, with 6 Buy ratings, 3 Hold ratings and 0 Sell ratings. The average 12-month target was JPY 2,358.90, with targets spanning JPY 1,900 to JPY 2,800.

Against the October 6 price of JPY 1,683.50, the average target lies 40.1 percent above the stock. The market range adds a useful counterweight: Santen's 52-week high is JPY 2,254, leaving the latest price 25.3 percent below that level.

Tokyo price and investor frame

Santen stock was last at JPY 1,683.50 on October 6, 2026, at 3:30 p.m. JST, with volume of 1,226,700 shares. Its market capitalization was JPY 541.6 billion, and the 52-week range was JPY 1,458 to JPY 2,254.